Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 1, 1985
Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection
C D Russell, P G Bischoff, F N Kontzen, et al.
Clinical Nutrition ESPEN
|
January 7, 2026
Valid food intake measures of adult patients for use within the GLIM framework: a scoping review
R Blaauw, G Bischoff, Mae de van der Schueren, et al.
Investigational New Drugs
|
November 11, 2019
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer
Johanna C Bendell, Helge G Bischoff, Jimmy Hwang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 10, 2012
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)
Sandra Gottschling, Esther Herpel, Wilfried E E Eberhardt, et al.
The Lancet. Oncology
|
February 10, 2020
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marina C Garassino, Shirish Gadgeel, Emilio Esteban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Marina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2002
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma
Ulrich Kaiser, Irmgard Uebelacker, Ulrich Abel, et al.
The New England Journal of Medicine
|
April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 1, 1985
Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection
C D Russell, P G Bischoff, F N Kontzen, et al.
Clinical Nutrition ESPEN
|
January 7, 2026
Valid food intake measures of adult patients for use within the GLIM framework: a scoping review
R Blaauw, G Bischoff, Mae de van der Schueren, et al.
Investigational New Drugs
|
November 11, 2019
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer
Johanna C Bendell, Helge G Bischoff, Jimmy Hwang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 10, 2012
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)
Sandra Gottschling, Esther Herpel, Wilfried E E Eberhardt, et al.
The Lancet. Oncology
|
February 10, 2020
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marina C Garassino, Shirish Gadgeel, Emilio Esteban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Marina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2002
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma
Ulrich Kaiser, Irmgard Uebelacker, Ulrich Abel, et al.
The New England Journal of Medicine
|
April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
Page
of 6